[{"address1": "2 Corporate Drive", "address2": "First Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 239 2030", "website": "https://www.sentibio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder, CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 868569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kanya  Rajangam M.D., Ph.D.", "age": 49, "title": "President, Head of Research & Development and Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 689991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 57, "title": "Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 58500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wilson  Wong Ph.D.", "title": "Scientific Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Li M.B.A.", "age": 63, "title": "Interim CFO, Treasurer & Principal Accounting Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas P. Chung", "title": "Vice President of Strategic Finance & Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dee Olomajeye Dragon", "title": "Vice President of People Strategy & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.45, "open": 4.92, "dayLow": 4.51, "dayHigh": 4.96, "regularMarketPreviousClose": 4.45, "regularMarketOpen": 4.92, "regularMarketDayLow": 4.51, "regularMarketDayHigh": 4.96, "beta": 2.746, "forwardPE": -2.5106382, "volume": 108694, "regularMarketVolume": 108694, "averageVolume": 2423450, "averageVolume10days": 100880, "averageDailyVolume10Day": 100880, "bid": 4.64, "ask": 4.85, "bidSize": 100, "askSize": 100, "marketCap": 21658380, "fiftyTwoWeekLow": 1.52, "fiftyTwoWeekHigh": 16.94, "priceToSalesTrailing12Months": 64.07805, "fiftyDayAverage": 4.07282, "twoHundredDayAverage": 3.09545, "currency": "USD", "enterpriseValue": 29638804, "floatShares": 2920793, "sharesOutstanding": 4588640, "sharesShort": 65095, "sharesShortPriorMonth": 69363, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.014199999, "heldPercentInsiders": 0.21004999, "heldPercentInstitutions": 0.23326999, "shortRatio": 3.27, "shortPercentOfFloat": 0.018, "impliedSharesOutstanding": 4588640, "bookValue": 14.642, "priceToBook": 0.3223603, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -78617000, "trailingEps": -15.59, "forwardEps": -0.75, "lastSplitFactor": "1:10", "lastSplitDate": 1721260800, "enterpriseToRevenue": 87.689, "enterpriseToEbitda": -0.524, "SandP52WeekChange": 0.23809385, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNTI", "underlyingSymbol": "SNTI", "shortName": "Senti Biosciences, Inc.", "longName": "Senti Biosciences, Inc.", "firstTradeDateEpochUtc": 1622035800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6e1c0497-dfb2-3427-8088-6f54c5e467cc", "messageBoardId": "finmb_538838857", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.72, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 15947000, "totalCashPerShare": 3.483, "ebitda": -56604000, "totalDebt": 35741000, "quickRatio": 3.817, "currentRatio": 4.89, "totalRevenue": 338000, "debtToEquity": 80.957, "revenuePerShare": 0.075, "returnOnAssets": -0.33019, "returnOnEquity": -1.11069, "grossProfits": -35805000, "freeCashflow": -57737876, "operatingCashflow": -42443000, "operatingMargins": -180.17455, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]